Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the tolerability and toxicity of different
dose of Anlotinib puls Pemetrexed/Docetaxel in Second-line Treatment of Advanced Gene
Negative Non-squamous Non-small Cell Lung Cancer , to provide a reference of dosage for Phase
II clinical trials